Want to see DHR full AI Analyst Report?
Earnings Data
Report Date
Jul 21, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
1.83Last Year’s EPS
1.8Same Quarter Last Year
Strong Buy
Based on 22 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call highlighted solid execution: strong earnings growth (+9.5% adjusted EPS), margin expansion, robust free cash flow, a raised full-year EPS range, clear momentum in bioprocessing (consumables growth and >30% equipment order growth), and constructive China trends. Management acknowledged near-term headwinds—chiefly a ~25% drop in respiratory revenue, Diagnostics weakness in China from VBP/reimbursement, and seasonally lower Q2 margins—but provided unchanged core revenue guidance (3%–6%), articulated remediation (DBS and identified Masimo synergies), and emphasized balance sheet strength and active M&A. Overall, positives (earnings, cash generation, bioprocessing momentum, product wins, M&A synergies) materially outweigh the moderated but manageable negatives (respiratory seasonality, China policy headwinds and instrument softness).Company Guidance
Revenue and Top-Line
Sales were $6.0 billion in Q1 2026; core revenue was up 0.5% year-over-year, with the rest of the business (ex-respiratory) growing ~3% year-over-year after a ~2.5% headwind from a lighter respiratory season.
Earnings, Margins and Cash Generation
Adjusted diluted net earnings per common share were $2.06, up 9.5% year-over-year; gross profit margin was 60.3%; adjusted operating profit margin was 30.2%, up 60 basis points year-over-year; free cash flow was $1.1 billion in Q1 with a free cash flow to net income conversion ratio of 105%.
Full‑Year Guidance and Raise
Full-year core revenue guidance unchanged at 3%–6%; raised full-year adjusted diluted net EPS guidance to $8.35–$8.55 (previously $8.35–$8.50); expect Q2 core revenue up low single digits and Q2 adjusted operating profit margin of ~26.5%.
Masimo Acquisition and Synergies
Announced pending acquisition of Masimo expected to be accretive in the first full year post-close and to deliver high single-digit ROIC by year five; management disclosed expected synergies of $125 million of cost synergies (including ~$50M gross margin and ~$50M OpEx plus ~$25M public company costs) and ~$50 million of revenue synergies realized by year five.
Biotechnology / Bioprocessing Strength
Biotechnology core revenue increased 7% and bioprocessing core revenue grew high single digits; consumables saw robust high-single-digit growth driven by commercial biologic production and notable strength in China; equipment orders were up more than 30% year-over-year (first orders growth in nearly two years).
Life Sciences Commercial Progress
Life Sciences core revenue increased 0.5%; consumables businesses grew low single digits, Aldevron grew on solid commercial execution, and Abcam showed improving revenue performance and meaningful margin expansion under DBS-driven execution.
Diagnostics Non‑Respiratory Momentum and New Products
Clinical diagnostics (ex-China) grew mid-single digits; Cepheid core non‑respiratory test menu grew mid-teens with 20% growth in sexual health and hospital-acquired infection assays; strong early demand for the Xpert GI multiplex panel and Beckman Coulter gained FDA clearance for HBc IgM enabling broader DxI 9000 menu.
China Recovery Signals
Management reported mid-single-digit core revenue growth in China overall and double-digit growth in bioprocessing in China in Q1, with improving funnel and order activity across Biotechnology and Life Sciences.
DHR Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
DHR Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Apr 21, 2026 | $195.09 | $194.14 | -0.49% |
Jan 28, 2026 | $234.76 | $223.60 | -4.76% |
Oct 21, 2025 | $207.23 | $219.54 | +5.94% |
Jul 22, 2025 | $186.69 | $188.52 | +0.98% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Danaher Corporation (DHR) report earnings?
Danaher Corporation (DHR) is schdueled to report earning on Jul 21, 2026, Before Open (Confirmed).
What is Danaher Corporation (DHR) earnings time?
Danaher Corporation (DHR) earnings time is at Jul 21, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is DHR EPS forecast?
DHR EPS forecast for the fiscal quarter 2026 (Q2) is 1.83.
